SCHEMBL10073785

SCHEMBL10073785

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccccc3)cc2)c(C)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.46
TNNI3K Q59H18 2/20 0.46
PDGFRA P16234 1/20 0.46
TEK Q02763 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
RAB9A P51151 3/20 0.43
CSF1R P07333 2/20 0.43
MAPK14 Q16539 3/20 0.43
BRAF P15056 2/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15494355 0.78 MTNR1A (0.34) KDRPDGFRARAB9AMAPK14BRAF
SCHEMBL21295431 0.71 STK39 (0.58) KDRPDGFRATEKMEN1KMT2A
SCHEMBL12362188 0.71 SMN1; SMN2 (0.63) KDRTNNI3KMEN1KMT2ARAB9A
SCHEMBL21295380 0.71 CA12 (0.71) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL10073790 0.70 CA12 (0.54) KDRTNNI3KTEKMEN1KMT2A
SCHEMBL8901288 0.70 HPGD (0.67) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL12391532 0.70 RAF1 (0.76) KDRTNNI3KPDGFRATEKMEN1
SCHEMBL30053559 0.69 CA12 (0.73) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL10084379 0.69 KDR (0.56) KDRTNNI3KPDGFRATEKMEN1
SCHEMBL10192075 0.69 KMT2A (0.71) KDRTNNI3KPDGFRAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 KDR 3633/4885TNNI3K 3300/4885PDGFRA 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.